Novel Malaria Vaccine Collaboration Announced by Protein Potential LLC and Aduro Biotech

ROCKVILLE, Md. & BERKELEY, Calif.--(BUSINESS WIRE)--Protein Potential LLC and Aduro BioTech, Inc. have been awarded a Phase 1 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop two novel malaria vaccines that will be administered in a sequential regimen. Both individual vaccines stimulate immune responses that target the circumsporozoite protein (CSP) antigen of Plasmodium falciparum, the parasite responsible for nearly all malaria deaths. The novel regimen is designed to induce the spectrum of immune responses that is believed to be essential for long-lasting protection against malaria.